Vident Advisory LLC Has $5.62 Million Position in Zoetis Inc. (NYSE:ZTS)

Vident Advisory LLC boosted its stake in Zoetis Inc. (NYSE:ZTS - Free Report) by 4.8% during the 4th quarter, according to the company in its most recent filing with the Securities and Exchange Commission (SEC). The institutional investor owned 34,482 shares of the company's stock after buying an additional 1,564 shares during the quarter. Vident Advisory LLC's holdings in Zoetis were worth $5,618,000 at the end of the most recent quarter.

Several other institutional investors have also bought and sold shares of the stock. Mission Wealth Management LP boosted its stake in Zoetis by 2.0% in the 4th quarter. Mission Wealth Management LP now owns 2,938 shares of the company's stock valued at $479,000 after buying an additional 59 shares in the last quarter. VeraBank N.A. boosted its stake in Zoetis by 4.1% in the 4th quarter. VeraBank N.A. now owns 1,562 shares of the company's stock valued at $254,000 after buying an additional 62 shares in the last quarter. HUB Investment Partners LLC boosted its stake in Zoetis by 4.7% in the 4th quarter. HUB Investment Partners LLC now owns 1,373 shares of the company's stock valued at $224,000 after buying an additional 62 shares in the last quarter. Coppell Advisory Solutions LLC boosted its stake in Zoetis by 18.0% in the 4th quarter. Coppell Advisory Solutions LLC now owns 420 shares of the company's stock valued at $68,000 after buying an additional 64 shares in the last quarter. Finally, Deseret Mutual Benefit Administrators boosted its stake in Zoetis by 6.6% in the 4th quarter. Deseret Mutual Benefit Administrators now owns 1,045 shares of the company's stock valued at $170,000 after buying an additional 65 shares in the last quarter. Institutional investors and hedge funds own 92.80% of the company's stock.

Insider Activity at Zoetis

In other Zoetis news, Director Willie M. Reed sold 1,210 shares of the stock in a transaction dated Tuesday, March 11th. The stock was sold at an average price of $166.14, for a total value of $201,029.40. Following the completion of the sale, the director now directly owns 11,245 shares in the company, valued at $1,868,244.30. This represents a 9.71% decrease in their ownership of the stock. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is available through the SEC website. Also, EVP Roxanne Lagano sold 326 shares of the stock in a transaction dated Monday, March 10th. The stock was sold at an average price of $170.00, for a total value of $55,420.00. Following the completion of the sale, the executive vice president now owns 15,781 shares of the company's stock, valued at $2,682,770. This trade represents a 2.02% decrease in their ownership of the stock. The disclosure for this sale can be found here. 0.18% of the stock is currently owned by corporate insiders.

Analyst Upgrades and Downgrades

ZTS has been the subject of several research analyst reports. Wall Street Zen upgraded Zoetis from a "hold" rating to a "buy" rating in a research report on Friday, March 7th. Barclays lifted their price objective on Zoetis from $242.00 to $244.00 and gave the company an "overweight" rating in a research report on Friday, February 14th. Stifel Nicolaus cut their price objective on Zoetis from $180.00 to $165.00 and set a "buy" rating for the company in a research report on Monday, April 14th. Morgan Stanley cut their price objective on Zoetis from $243.00 to $238.00 and set an "overweight" rating for the company in a research report on Friday, February 14th. Finally, UBS Group cut their price objective on Zoetis from $189.00 to $170.00 and set a "neutral" rating for the company in a research report on Wednesday, May 7th. One equities research analyst has rated the stock with a hold rating, eight have issued a buy rating and two have assigned a strong buy rating to the company. According to data from MarketBeat.com, Zoetis currently has an average rating of "Buy" and a consensus price target of $212.75.

Zoetis Trading Up 0.6%

Shares of ZTS stock traded up $0.95 on Friday, reaching $162.92. 2,732,205 shares of the stock were exchanged, compared to its average volume of 2,528,663. The stock has a market cap of $72.53 billion, a PE ratio of 29.78, a P/E/G ratio of 2.78 and a beta of 0.94. Zoetis Inc. has a one year low of $139.70 and a one year high of $200.33. The company has a debt-to-equity ratio of 1.09, a current ratio of 1.75 and a quick ratio of 1.08. The stock has a 50 day moving average price of $156.48 and a 200 day moving average price of $164.84.

Zoetis (NYSE:ZTS - Get Free Report) last released its quarterly earnings data on Tuesday, May 6th. The company reported $1.48 EPS for the quarter, beating analysts' consensus estimates of $1.40 by $0.08. The business had revenue of $2.22 billion during the quarter, compared to the consensus estimate of $2.20 billion. Zoetis had a return on equity of 53.82% and a net margin of 26.86%. The firm's revenue was up 1.4% on a year-over-year basis. During the same quarter in the prior year, the company posted $1.38 earnings per share. Equities research analysts forecast that Zoetis Inc. will post 6.07 EPS for the current fiscal year.

Zoetis Announces Dividend

The business also recently disclosed a quarterly dividend, which will be paid on Wednesday, September 3rd. Investors of record on Friday, July 18th will be issued a $0.50 dividend. The ex-dividend date of this dividend is Friday, July 18th. This represents a $2.00 dividend on an annualized basis and a yield of 1.23%. Zoetis's dividend payout ratio is presently 35.91%.

About Zoetis

Zoetis Inc engages in the discovery, development, manufacture, and commercialization of animal health medicines, vaccines, and diagnostic products and services in the United States and internationally. The company commercializes products primarily across species, including livestock, such as cattle, swine, poultry, fish, and sheep and others; and companion animals comprising dogs, cats, and horses.